Skip to main content
OpenTrials
Completed

NCT Number: NCT06844162

Pericapsular Nerve Group With Lateral Femoral Cutaneous Nerve Block vs Suprainguinal Fascia Iliaca Block for Analgesia in Total Hip Arthroplasty: A Prospective Comparative Study

Prospective observational cohort comparing analgesic efficacy of suprainguinal fascia iliaca block (SFIB) vs pericapsular nerve group block combined with lateral femoral cutaneous nerve block (PENG+LFCN) in primary total hip arthroplasty under general anesthesia (n=48). Outcomes include VAS pain at rest and with movement at 3, 12, 24, 48 h; morphine use (0-3, 3-12, 12-24, 24-48 h; total 0-48 h); quadriceps strength at 6 and 24 h; physiotherapy participation at 24 and 48 h; and adverse events within 48 h.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coxarthrosis; Primary Arthritis Joint Diseases Musculoskeletal Diseases Osteoarthritis Osteoarthritis, Hip Rheumatic Diseases

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Hacettepe University Hospitals

Ankara, 06230, Turkey (Türkiye)

About this study

Adults undergoing primary posterolateral THA under general anesthesia were included if they received either SFIB or PENG+LFCN. Pain (VAS at rest and with 45° passive flexion) was recorded at 3, 12, 24, and 48 h. Morphine via PCA was recorded for 0-3, 3-12, 12-24, and 24-48 h, with a 0-48 h total. Quadriceps strength (0-2 scale) was assessed at 6 and 24 h; physiotherapy participation at 24 and 48 h; opioid- or block-related adverse events through 48 h.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who are scheduled to undergo primary total hip arthroplasty with a diagnosis of coxarthosis

Exclusion criteria

  • Patients who have a history of neuropathy, patients with renal and hepatic insufficiency, patients with known coagulopathy, patients with a history of allergy to local anesthetics, patients with a history of inguinal surgery on the same side and patients with impaired mental status

Treatment and study plan

Primary outcomes

  1. Visual Analogue Scale scores

    Time frame: In the 48 hours following surgery

    Postoperative Visual Analogue Scale scores ( Minimum of 0 and maximum of 10 with higher scores indicative of more severe pain) will be measured at rest and 45 degrees passive flexion at 3, 12, 24 and 48th hours postoperatively

Secondary outcomes

  1. Opioid consumption

    Time frame: In the 48 hours following surgery

    Opioid consumption during 0-3,12-24, 24-48 hours and cumulative opioid consumption at 48h will be recorded following surgery

  2. Quadriceps weakness

    Time frame: In the 48 hours following surgery

    Quadriceps weakness will be assessed at 6 and 24th hours after surgery. The patient will be asked to extend the knee with the hip flexed at 45 degrees. Quadriceps strength will be graded according to the following: Grade 0: No extension, Grade 1: Extension against gravity but not against resistance, Grade 2: Extension against gravity and resistance.

  3. Ability to perform physiotherapy

    Time frame: In the 48 hours following surgery

    Ability to perform physiotherapy and whether the inability to perform physiotherapy was due to pain or motor weakness will be recorded by the physiotherapist at 24 and 48 hours after surgery

Other outcomes

  1. Adverse effects

    Time frame: In the 48 hours following surgery

    Any occurring adverse effects due to opioid use or nerve block will be recorded should they occur.

Sponsors and collaborators

Lead sponsor

Hacettepe University

Other

Registry information

Official study title

Comparison of Postoperative Analgesic Efficacy of Suprainguinal Fascia Iliaca Block (SFIB) and Pericapsular Nerve Group (PENG) Block With Lateral Femoral Cutaneous Nerve (LFCN) Block in Patients Undergoing Total Hip Arthroplasty

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Feb 25, 2025
Registry last updated
Aug 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.